ImmunoGen Stock News

U.S. stocks traded higher, with the Nasdaq gaining more than 200 points on Tuesday. Here are some big stocks recording losses in today’s session. AMMO, Inc. (NASDAQ: POWW) shares tumbled 26% to $2

ImmunoGen (IMGN) receives accelerated FDA approval for its lead drug mirvetuximab soravtansine-gynx, to be marketed as Elahere. The drug will treat adults with ovarian cancer.

Chardan Capital raised PDS Biotechnology Corporation (NASDAQ: PDSB) price target from $15 to $16. . Chardan Capital analyst Geulah Livshits maintained the stock with a Buy rating. PDS Biotechnology

U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session. Azenta, Inc. (NASDAQ: AZTA) shares jumped 35.7% to $63.27 in pre-marke

ImmunoGen (IMGN) reports a wider-than-expected loss in third-quarter 2022. Nevertheless, it beat revenue estimates. The company raises its financial guidance for 2022

ImmunoGen (IMGN) reports a wider-than-expected loss in third-quarter 2022. Nevertheless, it beat revenue estimates.

ImmunoGen, Inc. (NASDAQ:IMGN ) Q3 2022 Earnings Conference Call November 4, 2022 8:00 AM ET Company Participants Anabel Chan - Head, Investor Relations Mark Enyedy - President, CEO & Director Anna Ber

ImmunoGen (IMGN) delivered earnings and revenue surprises of -19.23% and 30.16%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

ImmunoGen (IMGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Cassava Sciences (SAVA) is expected to provide an update on its pipeline candidates during its third-quarter earnings.

Zoetis (ZTS) is anticipated to report positive earnings and revenues for third-quarter 2022. It will also provide an update on its pipeline on the earnings call.

ImmunoGen (IMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ImmunoGen has a PDUFA on November 28. The NDA is based on data from the Soraya trial.

On Agenus' (AGEN) third-quarter earnings call, investor focus is likely to be on the company's progress with the developments of its pipeline candidates.

On Novavax's (NVAX) third-quarter earnings call, investors' focus is likely to be on the sales figures of its COVID-19 vaccine.